Prevention of congestive heart failure and management of asymptomatic left ventricular dysfunction

British Medical Journal

Volumn 318, Issue 7195, 1999, Pages 1400-1402

  McKelvie, R S ^a   Benedict, C R ^b   Yusuf, S ^c  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; SIMVASTATIN;

CONGESTIVE HEART FAILURE; DIABETES MELLITUS; HEART DILATATION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE ISCHEMIA; HEART RATE; HEART VENTRICLE REMODELING; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MICROALBUMINURIA; NEUROENDOCRINE SYSTEM; OBESITY; PRIORITY JOURNAL; SHORT SURVEY; SMOKING; VITAL CAPACITY; ADULT; AGED; EVIDENCE BASED MEDICINE; FEMALE; HEART LEFT VENTRICLE FUNCTION; MALE; MIDDLE AGED; PATHOLOGY; REVIEW;

ADULT; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; EVIDENCE-BASED MEDICINE; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MIDDLE AGED; VENTRICULAR DYSFUNCTION, LEFT;

EID: 0033594583     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (32)

1. 1 Yamani M, Massie BM. Congestive heart failure: Insights from epidemiology, implications for treatment. Mayo Clin Proc 1993;68:1214-8.
2. 2 SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685-91.
3. 3 McDonagh TA, Morrison CE, Lawrence A, Ford I, Tunstall-Pedoe H, McMurray JJV, et al. Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population. Lancet 1997;350:829-33.
4. 4 McKelvie RS, Benedict CR, Yusuf S. Prevention of congestive heart failure and treatment of asymptomatic left ventricular dysfunction. In: Yusuf S, Cairus JA, Camm AJ, Fallen EL, Gersh BJ, eds. Evidence based cardiology. London: BMJ Publishing Group, 1998:703-21.
5. 5 Kjekshus J, Pedersen TR, Olsson AG, Eærgeman O, Pyörälä K on behalf of the 4S Study Group. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Cardiac Failure 1997;3:249-54.
6. 6 McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham study. N Engl J Med 1971;285:1441-6.
7. 7 Remes J, Reunanen A, Aromaa A, Pyörälä K. Incidence of heart failure in eastern Finland: a population-based surveillance study. Eur Heart J 1992;13:588-93.
8. 8 Kannel WB, Hjordand M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol 1974;34:29-34.
9. 9 Smith WM. Epidemiology of congestive heart failure. Am J Cardiol 1985;55:3-8A.
10. 10 Van Hoeven KH, Factor SM. A comparison of the pathological spectrum of hypertensive, diabetic, and hypertensive-diabetic heart disease. Circulation 1990;82:848-55.
11. 11 Suskin N, McKelvie RS, Wiecek E, Rouleau JL, Yusuf S. Insulin and glucose levels in heart failure (HF) [abstract]. Can J Cardiol 1997;13:C-103.
12. 12 Shindler DM, Kostis JB, Yusuf S, Quiñones MA, Pitt B, Stewart D, et al. Diabetes mellitus, a predictor of morbidity and mortality in the studies of left ventricular dysfunction (SOLVD) trials and registry. Am J Cardiol 1996;77:1017-20.
13. 13 The HOPE (Heart Outcome Prevention Evaluation) Study: the design of a large, simple randomized trial of an angiotensin converting enzyme inhibitor (ramipril) and Vitamin E in patients at risk of cardiovascular events. Can J Cardiol 1996;12:127-37.
14. 14 Gerstein HC, FeMann J, Zinman B, Bosch J, Pogue JM, Joyce C, et al. Albuminuria is highly prevalent and predicts cardiovascular events in high risk diabetic and nondiabeteic patients [abstract]. Circulation 1997;96(8 suppl):1225.
15. 15 Lauer MS, Evans JC, Levy D. Prognostic implications of subclinical left ventricular dilatation and systolic dysfunction in men free of overt cardiovascular disease (the Framingham heart study). Am J Cardiol 1992;70:1180-4.
16. 16 Francis GS, Goldsmith SR, Levine TB, Olivari MT, Cohn JN. The neurohumoral axis in congestive heart failure. Ann Intern Med 1984;101:370-7.
17. 17 Francis GS, Benedict C, Johnstone DE, Kirlin PC, Nicklas J, Liang C-S, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A sub-study of the studies of left ventricular dysfunction (SOLVD). Circulation 1990;82:1724-9.
18. 18 Benedict CR, Weiner DH, Johnstone DE, Bourassa MG, Ghali JK, Nicklas J, et al. Comparative neurohormonal responses in patients with preserved and impaired left ventricular ejection fraction: results of the studies of left ventricular dysfunction (SOLVD) registry. J Am Coll Cardiol 1993;22(suppl):146-153A.
19. 19 Benedict CR, Shelton B, Johnstone DE, Francis G, Greenberg B, Konstam M, et al. Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. Circulation 1996;94:690-7.
20. 20 Richards AM, Crozier IG, Yandle TG, Espiner EA, Ikram H, Nickols MG. Brain natriuretic factor: regional plasma concentrations and correlations with haemodynamic state in cardiac disease. Br Heart J 1993;69:414-7.
21. 21 Cody RJ, Atlas SA, Laragh JH, Kubo SH, Covit AB, Ryman KS, et al. Atrial natriuretic factor in human subjects and heart failure patients. J Clin Invest 1986;78:1362-74.
22. 22 Cowie MR, AD Struthers, DA Wood, AJS Coats, SG Thompson, PA Poole-Wilson, et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 1997;350:1347-51.
23. 23 McDonagh TA, Robb SD, Murdoch DR, Morton JJ, Ford I, Morrison CE, et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet 1998;351:9-13.
24. 24 Struthers AD. Plasma concentrations of brain natriuretic peptide: will this new test reduce the need for cardiac investigations? Br Heart J 1993;70:397-8.
25. 25 Vasan RS, Larson MG, Benjamin, EJ, Evans JC, Levy, D. Left ventricular dilation and the risk of congestive heart failure in people without myocardial infarction. N Engl J Med 1997;336:1350-5.
26. 26 Pouleur HG, Konstam MA, Udelson JE, Rousseau MF for the SOLVD Investigators. Changes in ventricular volume, wall thickness and wall stress during progression of left ventricular dysfunction. J Am Coll Cardiol 1993;22(suppl):43-8A.
27. 27 Pouleur H, Rousseau MF, van Eyll C, Melin J, Youngblood M, Yusuf S, et al. Cardiac mechanics during development of heart failure. Circulation 1993;87(suppl IV):14-20.
28. 28 Psaty BM, Smith NL, Siscovick DS, Koepsell TD, Weiss NS, Heckbert SR, et al. Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. JAMA 1997;277: 739-45.
29. 29 World Health Organisation-International Society of Hypertension Blood Pressure Lowering Treatment Trialists' Collaboration. Protocol for prospective collaborative overviews of major randomized trials of blood-pressure-lowering treatments. J Hypertens 1998;16:127-37.
30. 30 Yusuf S, Pepine CJ, Garces C, Pouleur H, Salem D, Kostis J, et al. Effect of enatapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 1992;340:1173-8.
31. 31 Rutherford JD, Pfeffer MA, Moyé LA, Davis BR, Flaker GC, Kowey PR, et al. Effects of captopril on ischemic events after myocardial infarction. Circulation 1994;90:1731-8.
32. 32 McKelvie RS, Yusuf S. Large trials and meta-analysis. In: Poole-Wilson PA, Colucci WS, Massie BM, Chatterjee K, Coats AJS, eds. Heart failure. Scientific principles and clinical practice. New York: Churchill Livingstone, 1997:597-615.